Pasithea Therapeutics Corp. KTTA
We take great care to ensure that the data presented and summarized in this overview for Pasithea Therapeutics Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in KTTA
Top Purchases
Top Sells
About KTTA
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Insider Transactions at KTTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2024
|
Alfred J Novak Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+44.0%
|
$13,750
$5.62 P/Share
|
|
Jun 12
2024
|
Alfred J Novak Director |
BUY
Grant, award, or other acquisition
|
Direct |
750
+50.0%
|
$3,750
$5.61 P/Share
|
|
Jun 02
2023
|
Lawrence Steinman Director |
BUY
Open market or private purchase
|
Direct |
30,000
+2.21%
|
$0
$0.43 P/Share
|
|
Nov 28
2022
|
Lawrence Steinman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+0.39%
|
$0
$0.98 P/Share
|
|
Nov 25
2022
|
Tiago Marques Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+0.24%
|
$2,000
$1.03 P/Share
|
|
Nov 23
2022
|
Tiago Marques Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,206
+0.29%
|
$7,206
$1.02 P/Share
|
|
Nov 22
2022
|
Lawrence Steinman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+0.39%
|
$0
$0.99 P/Share
|
|
Nov 17
2022
|
Simon Dumesnil Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+44.44%
|
$40,000
$1.06 P/Share
|
|
Nov 15
2022
|
Simon Dumesnil Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
$10,000
$1.07 P/Share
|
|
Oct 26
2022
|
Lawrence Steinman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+0.39%
|
$5,000
$1.1 P/Share
|
|
Oct 21
2022
|
Tiago Marques Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+0.31%
|
$5,000
$1.08 P/Share
|
|
Oct 17
2022
|
David Delaney |
BUY
Open market or private purchase
|
Indirect |
1,000
+0.44%
|
$1,000
$1.11 P/Share
|
|
Oct 17
2022
|
Lawrence Steinman Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+0.39%
|
$10,000
$1.14 P/Share
|
|
Sep 29
2022
|
Eric Shahinian |
BUY
Open market or private purchase
|
Indirect |
6,710
+0.37%
|
$6,710
$1.16 P/Share
|
|
Sep 28
2022
|
Eric Shahinian |
BUY
Open market or private purchase
|
Indirect |
57,647
+3.13%
|
$57,647
$1.19 P/Share
|
|
Sep 06
2022
|
Eric Shahinian |
BUY
Open market or private purchase
|
Indirect |
21,748
+1.25%
|
$21,748
$1.13 P/Share
|
|
Sep 02
2022
|
Eric Shahinian |
BUY
Open market or private purchase
|
Indirect |
11,507
+0.67%
|
$11,507
$1.14 P/Share
|
|
Sep 01
2022
|
Eric Shahinian |
BUY
Open market or private purchase
|
Indirect |
55,646
+3.19%
|
$55,646
$1.13 P/Share
|
|
Aug 30
2022
|
Eric Shahinian |
BUY
Open market or private purchase
|
Indirect |
17,828
+1.08%
|
$17,828
$1.15 P/Share
|
|
Aug 29
2022
|
Eric Shahinian |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.31%
|
$5,000
$1.17 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.5K shares |
|---|